Agios Pharmaceuticals, Inc. (0HB0.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
47.31-7.74 (-14.06%)
At close: 3:10PM GMT
| Previous close | 55.06 |
| Open | 47.50 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 47.31 - 47.50 |
| 52-week range | 47.31 - 47.50 |
| Volume | 65 |
| Avg. volume | N/A |
| Market cap | 2.151B |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.74 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.
- Motley Fool
Agios Pharmaceuticals Inc (AGIO) Q4 2020 Earnings Call Transcript
Image source: The Motley Fool. Agios Pharmaceuticals Inc (NASDAQ: AGIO)Q4 2020 Earnings CallFeb 25, 2021, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to Agios' Fourth Quarter 2020 Conference Call.
- Simply Wall St.
Introducing Agios Pharmaceuticals (NASDAQ:AGIO), A Stock That Climbed 41% In The Last Five Years
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
© 2021 Verizon Media. All rights reserved.
